Amgen’s Repatha was heralded recently in the media, generating headlines like "New Drug Prevents Heart Attacks in High-Risk Patients." But the company's stock then fell. Who should we believe and why?

Amgen’s cholesterol-lowering drug Repatha reduced the risk of heart attack and stroke by more than 20 percent in patients with heart disease, according to new data presented Friday at the American ...

A mid-cap biotech concern called The Medicines Group saw a 20% jump in its price Friday on the cardiovascular study results from Amgen's new cholesterol drug Repatha. The company is developing its own ...

Dear Dr. Roach: In a recent column, you wrote about reducing cholesterol with the help of statins along with a PCSK9i, such as Repatha or Praluent. My question is: Are these PCSK9is at all beneficial ...

A statin isn’t the only answer anymore to lowering cholesterol. The lipid-reducing medicines, among the most widely prescribed drugs in the U.S., have been a mainstay of heart-disease prevention and ...

The pharmaceutical sector mainstay earned several positive mentions in the pundit sphere that day. In Jim Cramer's "Stop Trading" segment on CNBC's Squawk on the Street program, the famous stock ...